{
    "2018-09-03": [
        [
            {
                "time": "2018-08-31",
                "original_text": "Why DexCom Soared 51.8% in August",
                "features": {
                    "keywords": [
                        "DexCom",
                        "Soared",
                        "51.8%",
                        "August"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-09-14",
                "original_text": "Sanofi's Blood Disorder Drug Cablivi Gets Approval in Europe",
                "features": {
                    "keywords": [
                        "Sanofi",
                        "Blood Disorder",
                        "Cablivi",
                        "Approval",
                        "Europe"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-31",
                "original_text": "Examining Eli Lilly’s Oncology Products’ Q2 2018 Performances",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Oncology",
                        "Q2",
                        "2018",
                        "Performances"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "oncology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-09-14",
                "original_text": "Sanofi's Blood Disorder Drug Cablivi Gets Approval in Europe",
                "features": {
                    "keywords": [
                        "Sanofi",
                        "Blood Disorder",
                        "Cablivi",
                        "Approval",
                        "Europe"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-31",
                "original_text": "Assessing Eli Lilly’s Human Pharmaceutical Segment in Q2 2018",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Human Pharmaceutical",
                        "Segment",
                        "Q2",
                        "2018"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}